Meridian Bioscience Commences Clinical Trials of Parvovirus B19 Vaccine

Meridian Bioscience announced the beginning of a Phase I/II Clinical Trial for a Parvovirus B19 Vaccine manufactured by its wholly owned subsidiary, Meridian Life Science.

The investigational new drug application for the Parvovirus B19 Vaccine was a collaborative effort between Meridian Life Science and two branches of the NIH, the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID).

Upon successful completion of the Phase I/II Clinical Trials, Meridian Life Science said plans to continue its collaboration with the NIH into Phase II and Phase III trials. The company added that it will be responsible for the manufacture of the vaccine, and will assume a greater role with respect to the regulatory aspects of the vaccine.